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Abstract
Background: Nasopharyngeal carcinoma (NPC) is a type of head-neck cancer with a distinguishable geographic
and racial distribution worldwide. Increasing evidence supports that the accumulation of additional genetic and
epigenetic abnormalities is important in driving the NPC tumorigenic process. In this study, we aim to investigate
the association between EIF5A2 (Eukaryotic translation initiation factor 5A2) expression status and NPC clinical
outcomes.
Methods: The expression status of EIF5A2 was investigated in the NPC tissue microarray. Tissues were from 166
NPC patients staging II-IV, collected between 1999 and 2005. All patients were administered 2–3 cycles of DDP
(cisplatin) + 5-Fu (5-fluorouracil) induction therapy and then treated with a uniform conventional two-dimensional
radiotherapy. Cell motility assay, tumor growth assay and cytotoxicity assay were performed on the EIF5A2
overexpressed cells and control cells. siRNA was also used in the in vitro studies.
Results: Positive staining of EIF5A2 was observed in 85.4 % (105/123) informative tumor cases. Multivariate analyses
demonstrated that EIF5A2 was an independent prognostic marker of poor overall survival (OS) (P = 0.041), failure-free
survival (FFS) (P = 0.029), and distant failure-free survival (D-FFS) (P = 0.043) in patients with locoregionally advanced
NPC patients treated with cisplatin + 5-Fu chemoradiotherapy. The forced expression of EIF5A2 in NPC cells enhanced
the cells’ motility and growth ability. Knock-down of EIF5A2 in NPC cells decreased the cell’s motility and growth
ability. Our results also demonstrated that EIF5A2 overexpression induced chemoresistance of NPC cells to 5-Fu.
Conclusions: Our findings suggested that EIF5A2 expression, as examined by immunohistochemistry, could function
as an independent prognostic factor of outcomes in NPC patients with cisplatin + 5-Fu chemoradiotherapy. EIF5A2
might be a novel therapeutic target for the inhibition of NPC progress.
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Background
Nasopharyngeal carcinoma (NPC) is a distinct epithelial
malignancy arising in the head and neck region. The dis-
ease demonstrates a strong geographic preference, with a
high prevalence in Southeast Asia and Southern China with
an annual incidence of 20 per 100, 000 people [1, 2]. The
mainstay of treatment for NPC is either radiotherapy or
combined chemo-radiotherapy, which demonstrates a cure
rate of over 90 % in early-stage patients [3]. However, the
outcomes for patients with loco-regional advanced disease
are still unsatisfactory even with the advanced radiotherapy
technique and combined chemotherapy [4, 5]. Significant
rates of metastasis or local relapse occur in these patients
after radiotherapy or combined chemo-radiotherapy.
Amplification of 3q26 was one of the most frequently
detected chromosomal aberration in NPC [6–9], suggest-
ing that candidate oncogene might exist in this region.
Eukaryotic translation initiation factor 5A2 (eIF5A2) is an
oncogene at 3q26. It shares 83 % amino acid identity with
EIF5A including the critical functional domain necessary
for maturation by hypusine modification [10, 11]. Unlike
EIF5A that is universally expressed in tissues, EIF5A2 is
only found in testis, brain and tumor tissues [12]. It has
been reported to be associated with many cancers: ovarian
cancer [13], hepatocellular carcinoma [14], non-small cell
lung cancer [15], bladder cancer [16] and colorectal car-
cinoma [17]. Although 3q26 amplification has been re-
ported in NPC, the expression of eIF5A2, located at
3q26.2, has not been investigated in NPC. In the present
study, we investigated the expression of EIF5A2 in NPC
tissue microarray. Our results indicated that EIF5A2 was
an independent adverse prognostic marker of overall
survival (OS), failure-free survival (FFS), and distant FFS
(D-FFS) in NPC patients. Functional study demonstrated
that overexpression of EIF5A2 increased cells’ motility
and growth ability. Our results also demonstrated that
EIF5A2 overexpression induced chemoresistance to 5-Fu
(5-fluorouracil) in NPC cells.
Methods
Cell culture
The immortalized nasopharyngeal epithelial cell line NP69
was a gift from Prof. G.S. Tsao [18]. The cells were cultured
in keratinocyte serum-free medium supplemented with
bovine pituitary extract (Invitrogen, Carlsbad, CA). The
NPC cell lines C666, CNE2, and HONE1 were cultured in
RPMI-1640 medium (Invitrogen, Carlsbad, CA) with 10 %
fetal bovine serum (FBS) (ExCell Bio, China). The cells were
cultured at 37 °C in a humidified chamber with 5 % CO2.
Tissue collection and immunohistochemistry (IHC)
NPC tumor tissues and non-tumor nasopharyngeal epi-
thelial tissues were collected at the Sun Yat-sen University
Cancer Center. The Committees for Ethical Review of
Research Involving Human Subjects at the Sun Yat-sen
University Cancer Center approved the use of the tissue
samples in the study. Written informed consent was ob-
tained from patients for the procurement of the tissue
samples. A tissue microarray (TMA) was constructed as
previously reported [19]. Tissues from 166 NPC patients
staging II-IV (AJCC/UICC-5), collected at the time of
diagnostic biopsy between 1999 and 2005, were included
in the TMA study. All patients were non-metastatic at the
time of diagnosis. All patients were administered 2–3 cy-
cles of DDP (cisplatin) + 5-Fu induction therapy and then
treated with a uniform conventional two-dimensional
radiotherapy protocol [20], in accordance with the treat-
ment policy for NPC at Sun Yat-sen University Cancer
Center. The regimen used for induction chemotherapy
was PF (DDP 100 mg/m2 IV on day 1 and 5-Fu 800 mg/
m2/d continuously IV on days 1–5). The accumulated ra-
diation doses were 66–78 Gy to the primary tumor and
60–70 Gy to the involved areas of the neck. Conventional
fractionated radiotherapy (2 Gy once daily, 5 times per
week) was applied in all cases. There were no treatment
delays or chemotherapy dose modifications secondary to
toxicity in the study. The median follow-up time was
6.6 years.
Slides were deparaffinized in xylene, rehydrated using
graded alcohol, immersed in 3 % hydrogen peroxide for
10 min to block endogenous peroxidase activity, and
antigen retrieved in EDTA buffer for 15 min. The slides
were incubated with 10 % goat serum at RT for 30 min,
followed by incubation in diluted EIF5A2 antibody
(1:50)(Wolwo, China) overnight at 4 °C. After incubation
with horseradish peroxidase-linked secondary antibody
(Real EnVision Detection Kit, Gene Tech, China) for
30 min, the slides were counterstained with Mayer’s
hematoxylin. The IHC results were evaluated independ-
ently by two pathologists. Expression of EIF5A2 was scored
as absent (absence of staining), very weak (faint staining in
<25 % of tumor cells), moderate (moderate staining in
25 % ~75 %, or strong staining in <25 % of tumor cells),
and strong (moderate staining in ≥75 %, or strong staining
in ≥25 % of tumor cells). In the present study, moderate/
strong staining was defined as positive staining and absent/
very weak staining as negative staining [21].
Western blotting
Cells were lysed in RIPA buffer (Cell Signaling Technology,
MA), and the cell lysates were separated by 12 % SDS-
PAGE and electrophoretically transferred to PVDF mem-
branes (Bio-Rad, CA) for blotting. Western blot results
were captured by traditional exposure or Automatic
Chemiluminescence Image Analysis System (Tanon 5200)
(Tanon Science & Technology Co., Ltd). EIF5A2 (Wolwo,
China) (1:1000) and actin (Cell Signaling Technology, MA)
were used in the study.
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NPC cell lines transduced with lentivirus expressing EIF5A2
LV105-eIF5A2 and LV105 (the empty vector) were bought
from GeneCopoeia (Guangzhou, China) and lentivirus was
packaged as the manufacturer’s protocol. NPC cells were
transduced with lenti-eIF5A2 and EIF5A2 overexpressed
NPC cells were established. The lentivirus packaged with
LV105 was used as vector control.
siRNA transfection assay
siRNA targeting eIF5A2 was ordered from GenePharma
(Shanghai, China). The sequences of siRNA were as
follows: 5’ CAUUCAAGAUGGUUACCUUtt 3’ (sense);
5’AAGGUAACCAUCUUGAAUGca 3’ (antisense). The
cells were transfected with siRNA using lipofectamine™
2000 (Invitrogen, Carlsbald, CA) as the protocol supplied
by the manufacturer.
Cell migration assay
Transwell Permeable Support (24-well plate) (Corning In-
corporated, NY) was used to assess the rate of cell migra-
tion. Cells in serum-free medium were seeded into the
upper chamber, while the lower chamber was filled with
medium with 10 % FBS. After incubation at 37 °C, pene-
trated cells to the lower surface of the filter were fixed,
stained and counted under a microscope. The assay was re-
peated three times.
The anchorage-dependent and -independent growth
assays
For the anchorage-dependent growth assay, 1 × 103 cells
were seeded into wells of 6-well plate. 10 days later, the sur-
viving colonies were fixed, stained with Crystal violet and
counted. Triplicate independent assays were performed.
Fig. 1 EIF5A2 expression was associated with poorer survival in NPC. a The EIF5A2 protein level was determined in immortalized nasopharyngeal
epithelial cell line NP69 and NPC cell lines (C666, CNE2 and HONE1). Actin was used as the loading control. b Representative pictures of immunostaining
of EIF5A2 in non-tumor nasopharyngeal tissue and in NPC tumor tissues (original magnification, 40 × objective). c Kaplan-Meier survival analysis of EIF5A2
expression in patients with NPC: EIF5A2 expression and the probability of OS of NPC patients (P= 0.066), FFS (P = 0.040), D-FFS (P = 0.048), and LR-FFS
(P = 0.277) in NPC patients
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For the anchorage-independent growth assay, 1 × 104 cells
were mixed with 0.4 % bactoagar on a bottom layer of
solidified 0.6 % bactoagar in 6-well plates. After 2 weeks,
colonies consisting of more than 50 cells were counted and
the assay was repeated three times.
Cytotoxicity assay
Cytotoxicity was determined using an XTT assay (CCK-
8, Dojindo, Kyushu, Japan). Cells were plated in 96-well
plates at the appropriate density. Twenty-four hours
later, cells were treated with 2-fold diluted concentra-
tions of 5-Fu (SunRise Ltd., Shanghai, China) for another
48 h at 37 °C. The XTT assay was performed according
to the manufacturer’s instructions. Three independent
assays were performed.
Statistical analysis
The data analysis was performed using the SPSS statistical
software package (SPSS 16.0, IL). Survival curves were gen-
erated according to the Kaplan-Meier method, and the
statistical analyses were performed using the log-rank test.
Univariate and multivariate survival analyses were per-
formed using Cox proportional hazards regression models.
The corresponding hazard ratio (HR) and 95 % CI were
generated from the Cox regression models. Pearson Chi-
square test was used to analyze the relationship between
EIF5A2 expression and clinic-pathological features. Stu-
dents’ t-test was used to analyze data from in vitro assays.
A P value less than 0.05 was considered statistically
significant.
Results
The expression of EIF5A2 was up-regulated in NPC cell lines
Western blotting analysis was used to detect the EIF5A2
expression in NPC cell lines. Compared with the immor-
talized nasopharyngeal epithelial cell line NP69, the ex-
pression of EIF5A2 was increased in the three tested
NPC cell lines (C666, CNE2 and HONE1) (Fig. 1a).
The expression of EIF5A2 was associated with poor
response rate and poor survival in NPC
The expression of EIF5A2 was also investigated by IHC
using a tissue microarray containing 166 NPC patients. In-
formative TMA results were obtained in 123 tumor cases.
The non-informative samples included lost samples and
samples with too few cells or with inappropriate staining.
Positive staining for EIF5A2 was observed in 105 of 123
(85.4 %) informative tumor tissues (Fig. 1b).
To examine the clinical significance of EIF5A2 expres-
sion in NPC, the correlation of EIF5A2 expression with
clinicopathologic features was investigated. The association
study showed that EIF5A2 expression was not significantly
associated with age, gender, T stage, N stage, staging or
WHO classification among the patients (Table 1). Among
the 105 patients with EIF5A2 expression, 68 (64.8 %)
had an objective response, as compared with 16 of 18
(88.9 %) patients without EIF5A2 expression (P = 0.042).
The Kaplan-Meier survival analysis revealed that EIF5A2
expression was associated with marginally poorer overall
survival (OS) in patients with NPC (log-rank test, P =
0.066) (Fig. 1c). EIF5A2 expression was significantly asso-
ciated with poorer failure-free survival (FFS) (log-rank
test, P = 0.040) and distant failure-free survival (D-FFS)
Table 1 Association of EIF5A2 expression with clinicopathologic
characteristics of NPC patients
EIF5A2 expression
Variable Total cases EIF5A2 (−) EIF5A2 (+) P valuea
Age 0.486
Mean(range) 45.6(21–75) 47 (33–59) 45.3 (21–75)
Gender 0.692
Male 103 14 (13.6 %) 89 (86.4 %)
Female 20 4 (20.0 %) 16 (80.0 %)
T stage 0.616
T1 3 0 (0) 3 (100 %)
T2 19 4 (21.1 %) 15 (78.9 %)
T3 59 9 (15.3 %) 50 (84.7 %)
T4 42 5 (11.9 %) 37 (88.1 %)
N stage 0.551
N0 10 1 (10.0 %) 9 (90.0 %)
N1 45 6 (13.3 %) 39 (86.7 %)
N2 43 5 (11.6 %) 38 (88.4 %)
N3 25 6 (24.0 %) 19 (76.0 %)
Staging 0.391
II 2 1 (50.0 %) 1 (50.0 %)
III 59 7 (11.9 %) 52 (88.1 %)
IV 62 10 (16.1 %) 52 (83.9 %)
WHO classification 1.0
II 7 1 (14.3 %) 6 (85.7 %)
III 116 17 (14.7 %) 99 (85.3 %)
aChi-square test
Table 2 Univariate and multivariate analyses of different
prognostic variables on patients’ overall survival (OS)
Variables Univariate analysis Multivariate analysis
HR (95 % CI) Pa HR (95 % CI) Pa
Age 1.028 (1.000–1.056) 0.049 1.042 (1.010–1.075) 0.011
Gender 0.681 (0.348–1.335) 0.263 0.866(0.383–1.957) 0.730
T stage 1.084 (0.789–1.490) 0.619 1.303(0.869–1.954) 0.200
N stage 1.12 (0.835–1.500) 0.450 1.381(0.990–1.927) 0.058
EIF5A2
expression
2.549(0.908–7.158) 0.076 2.949(1.046–8.313) 0.041
aCox regression model; HR, Hazards ratio; CI, confidence interval
Huang et al. BMC Cancer  (2016) 16:669 Page 4 of 9
(log-rank test, P = 0.048) (Fig. 1c). Locoregional failure-
free survival (LR-FFS) was also analyzed, and no signifi-
cant difference was observed between groups with positive
and negative EIF5A2 staining (log-rank test, P = 0.277)
(Fig. 1c). Univariate and multivariate analyses (age, gender,
T and N tumor categories, and EIF5A2 expression as
covariables) were performed, and the results are listed in
Tables 2 and 3. We found that EIF5A2 expression was a
prognostic factor for poor OS (P = 0.041), FFS (P = 0.029),
and D-FFS (P = 0.043), independent of age, gender, and T
and N stages, as evidenced by the multivariate analysis
(Table 3).
EIF5A2 enhanced NPC cells’ motility
Because EIF5A2 was reported to promote cells’ motility
in HCC and ESCC [14, 21], we were wondering whether
it could affect NPC cells’ motility. Cell migration assay
was performed on CNE2 cells transduced with lenti-
eIF5A2 and vector control cells. EIF5A2 protein level
was determined by western blotting (Fig. 2a). The results
demonstrated that cells migrating through transwell in-
creased in EIF5A2 enforced expression cells, compared
with vector control cells (Fig. 2b, P < 0.01). Similar re-
sults were observed in HONE1-EIF5A2 and HONE1-
Vec cells (Fig. 2a and b, P < 0.01). We next knocked
Table 3 Cox multivariate analyses of EIF5A2 on NPC patients’
survival
Significant factors Hazards ratio 95 % CI Pa
OS Age, per year increase 1.042 1.010–1.075 0.011
EIF5A2(+) vs. EIF5A2(−) 2.949 1.046–8.313 0.041
FFS EIF5A2(+) vs. EIF5A2(−) 3.128 1.122–8.715 0.029
D-FFS EIF5A2(+) vs. EIF5A2(−) 3.375 1.040–10.954 0.043
LR-FFS none
OS overall survival, FFS failure free survival, D-FFS distant failure-free survival,
LR-FFS localregional failure-free survival
aThe covariables: age, gender, T and N categories of NPC tumor, and
EIF5A2 expression
Fig. 2 EIF5A2 increased cells’ motility. a EIF5A2 protein level was determined in the CNE2 and HONE1 cells transduced with lenti-eIF5A2 and vector
control. Tubulin or actin was used as loading control. b Representative pictures and summary of cell migration assay demonstrated that cell motility
was increased in EIF5A2 overexpressed cells compared with vector control cells. c EIF5A2 was knocked down by siRNA in CNE2 and HONE1 cells. The
protein level was determined by WB. Actin was used as loading control. d Representative pictures and summary of cell migration assay demonstrated
that knock-down of EIF5A2 decreased cells’ motility. Original magnification: 10× objective
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down EIF5A2 with siRNA and found that cell motility de-
creased in CNE2-siRNA and HONE1-siRNA cells com-
pared with their corresponding control cells (Fig. 2c and d,
P < 0.01).
EIF5A2 promoted tumor cell growth
To determine the effect of EIF5A2 on NPC tumor cell
growth, anchorage-dependent and -independent growth
assays were performed on EIF5A2 overexpressed CNE2
cells (CNE2-EIF5A2) and vector-alone transfected cells
(CNE2-Vec). Results show that number of foci (P < 0.05)
(Fig. 3a) and colonies formed in the soft-agar (P < 0.01)
(Fig. 3b) increased in the EIF5A2 overexpressed cells
compared with the vector control cells. Taken together,
EIF5A2 overexpression increased the growth ability of
anchorage-dependent and -independent in CNE2 cells.
When we overexpressed EIF5A2 in HONE1 cells, similar
foci formation result was observed in HONE1-EIF5A2
cells compared with vector control cells (Fig. 3c, P < 0.05).
Silencing EIF5A2 in CNE2 also decreased the anchorage-
dependent and -independent growth ability of cells (Fig. 4a
and b, P < 0.01). Foci number decreased in EIF5A2 knock-
down HONE1 cells compared with scramble control cells
(Fig. 4c, P < 0.01).
EIF5A2 overexpression induced chemoresistance to 5-Fu
in NPC cells
We next asked whether EIF5A2 expression could induce che-
moresistance in NPC cells. XTT assays were used to evaluate
the chemosensitivity to 5-Fu between EIF5A2 overexpressed
cells (CNE2-EIF5A2 and HONE1-EIF5A2) and vector con-
trol cells (CNE2-Vec and HONE1-Vec). As shown in Fig. 5a
and b, the CNE2-EIF5A2 and HONE1-EIF5A2 cells were
more resistant to 5-Fu than their corresponding vector cells.
Discussion
NPC is a human malignancy exhibiting highly elevated
incidence rates in areas of southern China (including
Guangdong and the Hong Kong area). Epidemiologic
studies have indicated that environmental factors, includ-
ing EBV, exposure to nitrosamines in salted and pickled
foods and smoke, are associated with NPC initiation and
progression [22–24]. However, increasing evidence sup-
ports the hypothesis that persistent latent EBV in naso-
pharyngeal epithelial cells is dependent on the specific
existing genetic changes [25, 26]. Like other solid tumors,
NPC often demonstrates complex multiple chromosomal
aberrations. Accumulation of additional genetic and
Fig. 3 EIF5A2 promoted tumor cell growth. a Representative pictures
and summary of foci formation assay performed with CNE2-EIF5A2 and
vector control cells (CNE2-Vec). b Representative pictures and summary
of colony formation in soft-agar assay performed with CNE2-EIF5A2 and
CNE2-Vec cells. c Representative pictures and summary of foci formation
assay demonstrated that more foci were formed in HONE1-EIF5A2 than
HONE1-Vec cells
Fig. 4 Silencing EIF5A2 decreased tumor cell growth ability.
a Representative pictures and summary of foci formation assay
demonstrated that knock-down EIF5A2 decreased foci numbers in
CNE2 cells. b Representative pictures and summary of soft agar
assay demonstrated that colony number decreased in EIF5A2
knock-down CNE2 cells. c Representative pictures and summary of
foci formation assay demonstrated that knock-down EIF5A2 decreased
foci numbers in HONE1 cells
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epigenetic abnormalities is necessary for the tumori-
genic process [7]. Array-based comparative genomic
hybridization (CGH), fluorescence in situ hybridization
(FISH) and chromosome region-specific probes were
performed on NPC cell lines, xenograft and primary tu-
mors by different research groups [6–9], and 3q26 amplifi-
cation was identified as one of the most frequently
observed chromosomal aberrations in NPC, indicating
there might be candidate oncogenes located in this region.
According to the previous study, eIF5A2 (located at
3q26.2), has been significantly associated with the ad-
vanced stage of ovarian cancer and has been described
as an adverse prognostic marker of survival in stage I non-
small cell lung cancer patients and localized invasive blad-
der cancer [13, 15, 16]. It has been also associated with the
metastasis of various solid tumors, including colorectal,
esophageal and liver cancers [14, 17, 21]. In the current
study, the expression of EIF5A2 was identified to be in-
creased in the NPC cell lines compared with immortalized
nasopharyngeal epithelial cells. EIF5A2 enforced expression
could enhance NPC cells’ motility, anchorage-dependent
and -independent growth ability. The prognostic signifi-
cance of EIF5A2 expression was also evaluated in the NPC
TMA. Kaplan–Meier method analysis showed that EIF5A2
expression was associated with marginally OS in patients
with NPC (P = 0.066), poorer FFS (P = 0.040) and D-FFS (P
= 0.048). Multivariate analyses further demonstrated that
EIF5A2 was an independent adverse prognostic marker of
OS (P = 0.041), FFS (P = 0.029), and D-FFS (P = 0.043) in
NPC patients. EIF5A2 might therefore act as a prognostic
biomarker for NPC patients treated with cisplatin + 5-Fu
induction chemotherapy. NPC prognosis has been found to
be associated with some biomarkers based on individual
tumor characteristics: such as Epstein-Barr virus DNA [27],
epidermal growth factor receptor [28] and ERCC1 [29].
Whether EIF5A2 can integrate with these markers and
TNM stage to further improve prognostic prediction of
NPC patients need to be investigated in the future.
Radiation therapy combined with induction chemotherapy
is widely used in NPC treatment. The main treatment failure
for locoregionally advanced NPC is metastasis followed by
locoregional relapse, even with multiple cycles of chemother-
apy [30, 31]. In this study, the patients received the conven-
tional two-dimensional radiotherapy with DDP+ 5-Fu
induction therapy. The NPC patients with EIF5A2 expres-
sion had lower objective response compared with patients
without EIF5A2 expression (64.8 % vs 88.9 %, P= 0.042). It
suggested that EIF5A2 expression might be related to
chemotherapy or radiotherapy resistance. In fact, a higher
expression level of EIF5A2 has been reported to be corre-
lated with decreased doxorubicin sensitivity in breast cancer
cell lines [32], and ablation of EIF5A2 enhanced chemosensi-
tivity of HCC cells to 5-Fu [33]. In this study, the results also
demonstrated that EIF5A2 overexpression induced chemore-
sistance to 5-Fu in NPC cells. Taken together, EIF5A2 might
be a potential target of therapy in patients with NPC.
Conclusions
In the study described here, we revealed for the first time
that EIF5A2 was an independent adverse prognostic
marker of survival in patients with locoregionally ad-
vanced NPC treated with cisplatin + 5-Fu chemoradiother-
apy. In addition, EIF5A2 transduction into NPC cells
enhanced cells’ motility and growth ability. EIF5A2 over-
expression also induced chemoresistance to 5-Fu in NPC
cells. Our research suggests a novel therapeutic target for
the inhibition of NPC tumor progress.
Fig. 5 EIF5A2 overexpression induced chemoresistance to 5-Fu in
NPC cells. a CNE2-EIF5A2 cells are more chemoresistant than CNE2-
Vec cells at individual doses of 5-Fu (μM), as shown by XTT assay. b
HONE1-EIF5A2 cells are more chemoresistant than HONE1-Vec cells
at individual doses of 5-Fu (μM), as shown by XTT assay. (*, P < 0.05;
**, P < 0.01)
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Additional file
Additional file 1: Figure S1. (A and B) The immunostaining of EIF5A2
in tissue microarray of NPC tumor tissues. A, NPC TMA-1; B, NPC TMA-2.
(TIFF 3109 kb)
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